Gamma secretase inhibitors of Notch signaling

OncoTargets and Therapy

Volumn 6, Issue , 2013, Pages 943-955

  Olsauskas Kuprys, Roma ^a   Zlobin, Andrei ^a   Osipo, Clodia ^a  

^a LOYOLA UNIVERSITY HEALTH SYSTEM   (United States)

Author keywords

secretase; secretase inhibitors; Breast cancer; Combination breast cancer therapy; Signaling pathways

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; 8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; AZEPINE DERIVATIVE; CAPECITABINE; CARBOPLATIN; CEDIRANIB; DOCETAXEL; GAMMA SECRETASE INHIBITOR; LETROZOLE; LY 685458; MK 0752; MRK 003; N (6,7 DIHYDRO 6 OXO 5H DIBENZ[B,D]AZEPIN 7 YL) 2,2 DIMETHYL N' (2,2,3,3,3 PENTAFLUOROPROPYL)PROPANEDIAMIDE; N [N (3,5 DIFLUOROPHENACETYL)ALANYL]PHENYLGLYCINE TERT BUTYL ESTER; N2 [2 (3,5 DIFLUOROPHENYL) 2 HYDROXYACETYL] N1 (6,7 DIHYDRO 5 METHYL 6 OXO 5H DIBENZ[B,D]AZEPIN 7 YL)ALANINAMIDE; NOTCH RECEPTOR; PACLITAXEL; PF 3084014; RIDAFOROLIMUS; SEMAGACESTAT; SULFONAMIDE; TAMOXIFEN; UNCLASSIFIED DRUG; VISMODEGIB; YO 01027;

ADVANCED CANCER; ANTIANGIOGENIC ACTIVITY; BREAST CANCER; BREAST CARCINOGENESIS; BREAST METASTASIS; BREAST TUMOR; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; DIARRHEA; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; GASTROINTESTINAL SYMPTOM; HUMAN; LIGAND BINDING; METASTASIS; MOLECULAR INTERACTION; NONHUMAN; ONCOGENE; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; TRIPLE NEGATIVE BREAST CANCER;

EID: 84880815083     PISSN: 11786930     EISSN: None     Source Type: Journal    
DOI: 10.2147/OTT.S33766     Document Type: Review

References (139)

1. Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747-752.
2. Hu Z, Fan C, Oh DS, et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics. 2006;7(1):96.
3. Dexter JS. The analysis of a case of continuous variation in drosophila by a study of its linkage relations. Am Nat. 1914;48(576):712-758.
4. Morgan TH. The theory of the gene. Am Nat. 1917:513-544.
5. Morgan TH. The Physical Basis of Heredity. Philadelphia: JB Lippincott; 1919.
6. Kidd S, Kelley MR, Young MW. Sequence of the Notch locus of Drosophila melanogaster: relationship of the encoded protein to mammalian clotting and growth factors. Mol Cell Biol. 1986;6(9): 3094-3108.
7. Wharton KA, Johansen KM, Xu T, Artavanis-Tsakonas S. Nucleotide sequence from the neurogenic locus Notch implies a gene product that shares homology with proteins containing EGF-like repeats. Cell. 1985;43(3 Pt 2):567.
8. Lai EC. Notch signaling: control of cell communication and cell fate. Development. 2004;131(5):965-973.
9. Swiatek PJ, Lindsell CE, Del Amo FF, Weinmaster G, Gridley T. Notch1 is essential for postimplantation development in mice. Genes Dev. 1994;8(6):707-719.
10. Conlon RA, Reaume AG, Rossant J. Notch1 is required for the coordinate segmentation of somites. Development. 1995;121(5):1533-1545.
11. Jiang R, Lan Y, Chapman HD, et al. Defects in limb, craniofacial, and thymic development in Jagged2 mutant mice. Genes Dev. 1998;12(7): 1046-1057.
12. Hrabe de Angelis M, McIntyre IJ, Gossler A. Maintenance of somite borders in mice requires the Delta homologue DII1. Nature. 1997;386: 717-721.
13. Artavanis-Tsakonas S, Rand MD, Lake RJ. Notch signaling: cell fate control and signal integration in development. Science. 1999;284(5415):770-776.
14. Henrique D, Hirsinger E, Adam J, et al. Maintenance of neuroepithelial progenitor cells by Delta-Notch signalling in the embryonic chick retina. Curr Biol. 1997;7(9):661-670.
15. Neumann CJ, Cohen SM. A hierarchy of cross-regulation involving Notch, wingless, vestigial and cut organizes the dorsal/ventral axis of the Drosophila wing. Development. 1996;122(11):3477-3485.
16. de Celis JF, Garcia-Bellido A, Bray SJ. Activation and function of Notch at the dorsal-ventral boundary of the wing imaginal disc. Development. 1996;122(1):359-369.
17. Gaunt SJ. Developmental biology-chick limbs, fly wings and homology at the fringe. Nature. 1997;386(6623):324-325.
18. Moloney DJ, Panin VM, Johnston SH, et al. Fringe is a glycosyltransferase that modifies Notch. Nature. 2000;406(6794):369-375.
19. Haltiwanger RS, Stanley P. Modulation of receptor signaling by glycosylation: fringe is an O-fucose-β1, 3-N-acetylglucosaminyltransferase. Biochim Biophys Acta. 2002;1573(3):328-335.
20. Haines N, Irvine KD. Glycosylation regulates Notch signalling. Nat Rev Mol Cell Biol. 2003;4(10):786-797.
21. Blaumueller CM, Qi H, Zagouras P, Artavanis-Tsakonas S. Intracellular cleavage of Notch leads to a heterodimeric receptor on the plasma membrane. Cell. 1997;90(2):281-291.
22. Logeat F, Bessia C, Brou C, et al. The Notch1 receptor is cleaved constitutively by a furin-like convertase. Proc Natl Acad Sci U S A. 1998;95(14):8108-8112.
23. Bettenhausen B, de Angelis MH, Simon D, Guénet JL, Gossler A. Transient and restricted expression during mouse embryogenesis of Dll1, a murine gene closely related to Drosophila Delta. Development. 1995;121(8):2407-2418.
24. Dunwoodie SL, Henrique D, Harrison SM, Beddington R. Mouse Dll3: a novel divergent Delta gene which may complement the function of other Delta homologues during early pattern formation in the mouse embryo. Development. 1997;124(16):3065-3076.
25. Shutter JR, Scully S, Fan W, et al. Dll4, a novel Notch ligand expressed in arterial endothelium. Genes Dev. 2000;14(11):1313-1318.
26. Lindsell CE, Shawber CJ, Boulter J, Weinmaster G. Jagged: a mammalian ligand that activates Notch1. Cell. 1995;80(6):909-917.
27. Bray SJ. Notch signalling: a simple pathway becomes complex. Nat Rev Mol Cell Biol. 2006;7(9):678-689.
28. Miele L. Notch signaling. Clin Cancer Res. 2006;12(4):1074-1079.
29. Kopan R, Ilagan MXG. The canonical Notch signaling pathway: unfolding the activation mechanism. Cell. 2009;137(2):216-233.
30. Mumm JS, Kopan R. Notch signaling: from the outside in. Dev Biol. 2000;228(2):151.
31. Brou C, Logeat F, Gupta N, et al. A novel proteolytic cleavage involved in Notch signaling: the role of the disintegrin-metalloprotease TACE. Mol Cell. 2000;5(2):207-216.
32. Reiss K, Saftig P. The "a disintegrin and metalloprotease"(ADAM) family of sheddases: physiological and cellular functions. Semin Cell Dev Biol. 2009;20(2):126-137.
33. Mumm JS, Schroeter EH, Saxena MT, et al. A ligand-induced extracellular cleavage regulates-secretase-like proteolytic activation of Notch1. Mol Cell. 2000;5(2):197-206.
34. Lleo M. Activity of gamma-secretase on substrates other than APP. Curr Top Med Chem. 2008;8(1):9-16.
35. De Strooper B. Aph-1, Pen-2, and nicastrin with presenilin generate an active gamma-secretase complex. Neuron. 2003;38(1):9-12.
36. Lai EC. Notch cleavage: nicastrin helps presenilin make the final cut. Curr Biol. 2002;12(6):R200-R202.
37. Schroeter EH, Kisslinger JA, Kopan R. Notch-1 signalling requires ligand-induced proteolytic release of intracellular domain. Nature. 1998;393(6683):382-386.
38. Struhl K. Histone acetylation and transcriptional regulatory mechanisms. Genes Dev. 1998;12(5):599-606.
39. Wu G, Lyapina S, Das I, et al. SEL-10 is an inhibitor of Notch signaling that targets Notch for ubiquitin-mediated protein degradation. Mol Cell Biol. 2001;21(21):7403-7415.
40. Ellisen LW, Bird J, West DC, et al. TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell. 1991;66(4):649-661.
41. Weng AP, Ferrando AA, Lee W, et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science. 2004;306(5694):269-271.
42. Fabbri G, Rasi S, Rossi D, et al. Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. J Exp Med. 2011;208(7):1389-1401.
43. Morimura T, Goitsuka R, Zhang Y, Saito I, Reth M, Kitamura D. Cell cycle arrest and apoptosis induced by Notch1 in B cells. J Biol Chem. 2000;275(47):36523-36531.
44. Romer S, Saunders U, Jäck H, Jehn B. Notch1 enhances B-cell receptor-induced apoptosis in mature activated B cells without affecting cell cycle progression and surface IgM expression. Cell Death Differ. 2003;10(7): 833-844.
45. Nefedova Y, Cheng P, Alsina M, Dalton WS, Gabrilovich DI. Involvement of Notch-1 signaling in bone marrow stroma-mediated de novo drug resistance of myeloma and other malignant lymphoid cell lines. Blood. 2004;103(9):3503-3510.
46. Hubmann R, Schwarzmeier JD, Shehata M, et al. Notch2 is involved in the overexpression of CD23 in B-cell chronic lymphocytic leukemia. Blood. 2002;99(10):3742-3747.
47. Jundt F, Anagnostopoulos I, Förster R, Mathas S, Stein H, Dörken B. Activated Notch1 signaling promotes tumor cell proliferation and survival in Hodgkin and anaplastic large cell lymphoma. Blood. 2002;99(9):3398-3403.
48. Jundt F, Pröbsting KS, Anagnostopoulos I, et al. Jagged1-induced Notch signaling drives proliferation of multiple myeloma cells. Blood. 2004;103(9):3511-3515.
49. Kridel R, Meissner B, Rogic S, et al. Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma. Blood. 2012;119(9):1963-1971.
50. Lee S, Kumano K, Nakazaki K, et al. Gain-of-function mutations and copy number increases of Notch2 in diffuse large B-cell lymphoma. Cancer Sci. 2009;100(5):920-926.
51. Houde C, Li Y, Song L, et al. Overexpression of the NOTCH ligand JAG2 in malignant plasma cells from multiple myeloma patients and cell lines. Blood. 2004;104(12):3697-3704.
52. Zagouras P, Stifani S, Blaumueller CM, Carcangiu ML, Artavanis-Tsakonas S. Alterations in Notch signaling in neoplastic lesions of the human cervix. Proc Natl Acad Sci U S A. 1995;92(14):6414-6418.
53. Weijzen S, Zlobin A, Braid M, Miele L, Kast WM. HPV16 E6 and E7 oncoproteins regulate Notch-1 expression and cooperate to induce transformation. J Cell Physiol. 2003;194(3):356-362.
54. May R, Riehl TE, Hunt C, Sureban SM, Anant S, Houchen CW. Identification of a novel putative gastrointestinal stem cell and adenoma stem cell marker, doublecortin and CaM kinase-like-1, following radiation injury and in adenomatous polyposis coli/multiple intestinal neoplasia mice. Stem Cells. 2007;26(3):630-637.
55. Akiyoshi T, Nakamura M, Yanai K, et al. γ-Secretase inhibitors enhance taxane-induced mitotic arrest and apoptosis in colon cancer cells. Gastroenterology. 2008;134(1):131-144.
56. Gao B, Jeong WI, Tian Z. Liver: an organ with predominant innate immunity. Hepatology. 2007;47(2):729-736.
57. Qi R, An H, Yu Y, et al. Notch1 signaling inhibits growth of human hepatocellular carcinoma through induction of cell cycle arrest and apoptosis. Cancer Res. 2003;63(23):8323-8329.
58. Konishi J, Kawaguchi KS, Vo H, et al. γ-Secretase inhibitor prevents Notch3 activation and reduces proliferation in human lung cancers. Cancer Res. 2007;67(17):8051-8057.
59. Terris B, Blaveri E, Crnogorac-Jurcevic T, et al. Characterization of gene expression profiles in intraductal papillary-mucinous tumors of the pancreas. Am J Pathol. 2002;160(5):1745-1754.
60. Miyamoto Y, Maitra A, Ghosh B, et al. Notch mediates TGFα-induced changes in epithelial differentiation during pancreatic tumorigenesis. Cancer Cell. 2003;3(6):565-576.
61. Wang Z, Zhang Y, Li Y, Banerjee S, Liao J, Sarkar FH. Down-regulation of Notch-1 contributes to cell growth inhibition and apoptosis in pancreatic cancer cells. Mol Cancer Ther. 2006;5(3):483-493.
62. Kimura K, Satoh K, Kanno A, et al. Activation of Notch signaling in tumorigenesis of experimental pancreatic cancer induced by dimethylbenzanthracene in mice. Cancer Sci. 2007;98(2):155-162.
63. Santagata S, Demichelis F, Riva A, et al. JAGGED1 expression is associated with prostate cancer metastasis and recurrence. Cancer Res. 2004;64(19):6854-6857.
64. Ramdas L, Giri U, Ashorn CL, et al. miRNA expression profiles in head and neck squamous cell carcinoma and adjacent normal tissue. Head Neck. 2009;31(5):642-654.
65. Park JT, Li M, Nakayama K, et al. Notch3 gene amplification in ovarian cancer. Cancer Res. 2006;66(12):6312-6318.
66. Rose SL, Kunnimalaiyaan M, Drenzek J, Seiler N. Notch 1 signaling is active in ovarian cancer. Gynecol Oncol. 2010;117(1):130-133.
67. Sjolund J, Johansson M, Manna S, et al. Suppression of renal cell carcinoma growth by inhibition of Notch signaling in vitro and in vivo. J Clin Invest. 2008;118(1):217-228.
68. Miele L, Miao H, Nickoloff B. NOTCH signaling as a novel cancer therapeutic target. Curr Cancer Drug Targets. 2006;6(4):313-323.
69. Joutel A, Tournier-Lasserve E. Notch signalling pathway and human diseases. Semin Cell Dev Biol. 1998;9(6):619-625.
70. Nickoloff BJ, Osborne BA, Miele L. Notch signaling as a therapeutic target in cancer: a new approach to the development of cell fate modifying agents. Oncogene. 2003;22(42):6598-6608.
71. Miele L, Osborne B. Arbiter of differentiation and death: Notch signaling meets apoptosis. J Cell Physiol. 1999;181(3):393-409.
72. Al-Hussaini H, Subramanyam D, Reedijk M, Sridhar SS. Notch signaling pathway as a therapeutic target in breast cancer. Mol Cancer Ther. 2011;10(1):9-15.
73. Leong KG, Karsan A. Recent insights into the role of Notch signaling in tumorigenesis. Blood. 2006;107(6):2223-2233.
74. Radtke F, Raj K. The role of Notch in tumorigenesis: oncogene or tumour suppressor? Nat Rev Cancer. 2003;3(10):756-767.
75. Wilson A, Radtke F. Multiple functions of Notch signaling in self-renewing organs and cancer. FEBS Lett. 2006;580(12):2860-2868.
76. Roy M, Pear WS, Aster JC. The multifaceted role of Notch in cancer. Curr Opin Genet Dev. 2007;17(1):52-59.
77. Maillard I, Pear WS. Notch and cancer: best to avoid the ups and downs. Cancer Cell. 2003;3(3):203-205.
78. Miele L, Golde T, Osborne B. Notch signaling in cancer. Curr Mol Med. 2006;6(8):905-918.
79. Ranganathan P, Weaver KL, Capobianco AJ. Notch signalling in solid tumours: a little bit of everything but not all the time. Nat Rev Cancer. 2011;11(5):338-351.
80. Kiaris H, Politi K, Grimm LM, et al. Modulation of Notch signaling elicits signature tumors and inhibits hras1-induced oncogenesis in the mouse mammary epithelium. Am J Pathol. 2004;165(2):695-705.
81. Hu C, Diévart A, Lupien M, Calvo E, Tremblay G, Jolicoeur P. Overexpression of activated murine Notch1 and Notch3 in transgenic mice blocks mammary gland development and induces mammary tumors. Am J Pathol. 2006;168(3):973-990.
82. Klinakis A, Szabolcs M, Politi K, Kiaris H, Artavanis-Tsakonas S, Efstratiadis A. Myc is a Notch1 transcriptional target and a requisite for Notch1-induced mammary tumorigenesis in mice. Proc Natl Acad Sci U S A. 2006;103(24):9262-9267.
83. Politi K, Feirt N, Kitajewski J. Notch in mammary gland development and breast cancer. Semin Cancer Biol. 2004;14(5):341-347.
84. Diévart A, Beaulieu N, Jolicoeur P. Involvement of Notch1 in the development of mouse mammary tumors. Oncogene. 1999;18(44): 5973-5981.
85. Smith GH, Gallahan D, Diella F, Jhappan C, Merlino G, Callahan R. Constitutive expression of a truncated INT3 gene in mouse mammary epithelium impairs differentiation and functional development. Cell Growth Differ. 1995;6(5):563-577.
86. Gallahan D, Callahan R. The mouse mammary tumor associated gene INT3 is a unique member of the NOTCH gene family (NOTCH4). Oncogene. 1997;14(16):1883-1890.
87. Gallahan D, Jhappan C, Robinson G, et al. Expression of a truncated Int3 gene in developing secretory mammary epithelium specifically retards lobular differentiation resulting in tumorigenesis. Cancer Res. 1996;56(8):1775-1785.
88. Robinson DR, Kalyana-Sundaram S, Wu YM, et al. Functionally recurrent rearrangements of the MAST kinase and Notch gene families in breast cancer. Nat Med. 2011;17(12):1646-1651.
89. Xiao Y, Ye Y, Zou X, et al. The lymphovascular embolus of inflammatory breast cancer exhibits a Notch 3 addiction. Oncogene. 2010;30(3): 287-300.
90. Konstantinos T. Expression of Notch receptors in primary breast cancer and correlation with pathological features. Clin Exp Pharmacol. 2012;2:1000109.
91. Rizzo P, Miao H, D'Souza G, et al. Cross-talk between Notch and the estrogen receptor in breast cancer suggests novel therapeutic approaches. Cancer Res. 2008;68(13):5226-5235.
92. Yamaguchi N, Oyama T, Ito E, et al. NOTCH3 signaling pathway plays crucial roles in the proliferation of ErbB2-negative human breast cancer cells. Cancer Res. 2008;68(6):1881-1888.
93. Stylianou S, Clarke RB, Brennan K. Aberrant activation of Notch signaling in human breast cancer. Cancer Res. 2006;66(3): 1517-1525.
94. Reedijk M, Odorcic S, Chang L, et al. High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival. Cancer Res. 2005;65(18):8530-8537.
95. Dickson BC, Mulligan AM, Zhang H, et al. High-level JAG1 mRNA and protein predict poor outcome in breast cancer. Mod Pathol. 2007;20(6):685-693.
96. Parr C, Watkins G, Jiang W. The possible correlation of Notch-1 and Notch-2 with clinical outcome and tumour clinicopathological parameters in human breast cancer. Int J Mol Med. 2004;14(5): 779-786.
97. Shimizu K, Chiba S, Saito T, Kumano K, Hamada Y, Hirai H. Functional diversity among Notch1, Notch2, and Notch3 receptors. Biochem Biophys Res Commun. 2002;291(4):775-779.
98. O'Neill CF, Urs S, Cinelli C, et al. Notch2 signaling induces apoptosis and inhibits human MDA-MB-231 xenograft growth. Am J Pathol. 2007;171(3):1023-1036.
99. Harrison H, Farnie G, Howell SJ, et al. Regulation of breast cancer stem cell activity by signaling through the Notch4 receptor. Cancer Res. 2010;70(2):709-718.
100. Grudzien P, Lo S, Albain KS, et al. Inhibition of Notch signaling reduces the stem-like population of breast cancer cells and prevents mammosphere formation. Anticancer Res. 2010;30(10):3853-3867.
101. Pece S, Serresi M, Santolini E, et al. Loss of negative regulation by Numb over Notch is relevant to human breast carcinogenesis. J Cell Biol. 2004;167(2):215-221.
102. To M, Gokgoz N, Doyle T, et al. Functional characterization of novel presenilin-2 variants identified in human breast cancers. Oncogene. 2006;25(25):3557-3564.
103. Klinakis A, Lobry C, Abdel-Wahab O, et al. A novel tumour-suppressor function for the Notch pathway in myeloid leukaemia. Nature. 2011;473(7346):230-233.
104. Nicolas M, Wolfer A, Raj K, et al. Notch1 functions as a tumor suppressor in mouse skin. Nat Genet. 2003;33(3):416-421.
105. Allenspach EJ, Maillard I, Aster JC, Pear WS. Notch signaling in cancer. Cancer Biol Ther. 2002;1(5):460-460.
106. Imatani A, Callahan R. Identification of a novel NOTCH-4/INT-3 RNA species encoding an activated gene product in certain human tumor cell lines. Oncogene. 2000;19(2):223-231.
107. Soares R, Balogh G, Guo S, Gärtner F, Russo J, Schmitt F. Evidence for the Notch signaling pathway on the role of estrogen in angiogenesis. Mol Endocrinol. 2004;18(9):2333-2343.
108. Hao L. Notch-1 Activates Estrogen Receptor Alpha-Dependent Transcription via IKK Alpha. Loyola University Chicago; 2010.
109. Zhang Z, Wang H, Ikeda S, et al. Notch3 in human breast cancer cell lines regulates osteoblast-cancer cell interactions and osteolytic bone metastasis. Am J Pathol. 2010;177(3):1459-1469.
110. Hurlbut GD, Kankel MW, Lake RJ, Artavanis-Tsakonas S. Crossing paths with Notch in the hyper-network. Curr Opin Cell Biol. 2007;19(2):166-175.
111. Guo S, Liu M, Gonzalez-Perez RR. Role of Notch and its oncogenic signaling crosstalk in breast cancer. Biochim Biophys Acta. 2011;1815(2):197-213.
112. Song LL, Peng Y, Yun J, et al. Notch-1 associates with IKK alpha and regulates IKK activity in cervical cancer cells. Oncogene. 2008;27(44):5833-5844.
113. Osipo C, Golde TE, Osborne BA, Miele LA. Off the beaten pathway: the complex cross talk between Notch and NF-κB. Lab Invest. 2007;88(1):11-17.
114. Osipo C, Patel P, Rizzo P, et al. ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a γ-secretase inhibitor. Oncogene. 2008;27(37):5019-5032.
115. Pandya K, Meeke K, Clementz A, et al. Targeting both Notch and ErbB-2 signalling pathways is required for prevention of ErbB-2-positive breast tumour recurrence. Br J Cancer. 2011;105(6): 796-806.
116. Mehta K, Osipo C. Trastuzumab resistance: role for Notch signaling. Sci World J. 2009;9:1438-1448.
117. Clementz AG, Rogowski A, Pandya K, Miele L, Osipo C. Notch-1 and Notch-4 are novel gene targets of PEA3 in breast cancer: novel therapeutic implications. Breast Cancer Res. 2011;13(3):R63.
118. Olson RE, Albright CF. Recent progress in the medicinal chemistry of-secretase inhibitors. Curr Top Med Chem. 2008;8(1):17-33.
119. Kreft AF, Martone R, Porte A. Recent advances in the identification of γ-secretase inhibitors to clinically test the Aβ oligomer hypothesis of Alzheimer's disease. J Med Chem. 2009;52(20):6169-6188.
120. Clarke EE, Churcher I, Ellis S, et al. Intra-or intercomplex binding to the γ-secretase enzyme. J Biol Chem. 2006;281(42):31279-31289.
121. Wong GT, Manfra D, Poulet FM, et al. Chronic treatment with the γ-secretase inhibitor LY-411,575 inhibits β-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J Biol Chem. 2004;279(13):12876-12882.
122. Yao J, Duan L, Fan M, Wu X. γ-secretase inhibitors exerts antitumor activity via down-regulation of Notch and Nuclear factor kappa B in human tongue carcinoma cells. Oral Dis. 2007;13(6):555-563.
123. Séveno C, Loussouarn D, Bréchet S, Campone M, Juin P, Barillé-Nion S. γ-Secretase inhibition promotes cell death, Noxa upregulation, and sensitization to BH3 mimetic ABT-737 in human breast cancer cells. Breast Cancer Res. 2012;14(3):R96.
124. Zeng Q, Li S, Chepeha DB, et al. Crosstalk between tumor and endothelial cells promotes tumor angiogenesis by MAPK activation of Notch signaling. Cancer Cell. 2005;8(1):13-23.
125. Dovey H, John V, Anderson J, et al. Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain. J Neurochem. 2009;76(1):173-181.
126. Purow B. Notch inhibition as a promising new approach to cancer therapy. Adv Exp Med Biol. 2012;727:305-319.
127. Meurette O, Stylianou S, Rock R, Collu GM, Gilmore AP, Brennan K. Notch activation induces Akt signaling via an autocrine loop to prevent apoptosis in breast epithelial cells. Cancer Res. 2009;69(12): 5015-5022.
128. Robinson DR, Kalyana-Sundaram S, Wu Y-M, et al. Functionally recurrent rearrangements of the MAST kinase and Notch gene families in breast cancer. Nat Med. 2011;17(12):1646-1651.
129. Siemers E, Skinner M, Dean RA, et al. Safety, tolerability, and changes in amyloid beta concentrations after administration of a gamma-secretase inhibitor in volunteers. Clin Neuropharmacol. 2005;28(3): 126-132.
130. Wei P, Walls M, Qiu M, et al. Evaluation of selective γ-secretase inhibitor PF-03084014 for its antitumor efficacy and gastrointestinal safety to guide optimal clinical trial design. Mol Cancer Ther. 2010;9(6): 1618-1628.
131. Zhang CC, Pavlicek A, Zhang Q, et al. Biomarker and pharmacologic evaluation of the γ-secretase inhibitor PF-03084014 in breast cancer models. Clin Cancer Res. 2012;18(18):5008-5019.
132. Tolcher A, Mikulski S, Messersmith W, et al. A phase I study of R04929097, a novel gamma secretase inhibitor, in patients with advanced solid tumors. J Clin Oncol (Meeting Abstracts). 2010;28(Suppl 15):2502.
133. Tolcher AW, Messersmith WA, Mikulski SM, et al. Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors. J Clin Oncol. 2012;30(19):2348-2353.
134. He W, Luistro L, Carvajal D, et al. High tumor levels of IL6 and IL8 abrogate preclinical efficacy of the γ-secretase inhibitor, RO4929097. Mol Oncol. 2011;5(3):292-301.
135. Luistro L, He W, Smith M, et al. Preclinical profile of a potent γ-secretase inhibitor targeting Notch signaling with in vivo efficacy and pharmacodynamic properties. Cancer Res. 2009;69(19):7672-7680.
136. Wu J, LoRusso PM, Matherly LH, Li J. Implications of plasma protein binding for pharmacokinetics and pharmacodynamics of the γ-secretase inhibitor RO4929097. Clin Cancer Res. 2012;18(7):2066-2079.
137. Barten DM, Meredith JE, Zaczek R, Houston JG, Albright CF. Gamma-secretase inhibitors for Alzheimers disease: balancing efficacy and toxicity. Drugs R D. 2006;7(2):87-97.
138. Wu Y, Cain-Hom C, Choy L, et al. Therapeutic antibody targeting of individual Notch receptors. Nature. 2010;464(7291):1052-1057.
139. Rizzo P, Osipo C, Foreman K, Golde T, Osborne B, Miele L. Rational targeting of Notch signaling in cancer. Oncogene. 2008;27(38): 5124-5131.